Lilly Asia Ventures
Tao Yu, Ph.D., is a Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Tao was an Engagement Manager and a core member of Healthcare Practice at McKinsey Greater China, serving pharma and medtech companies across different strategy topics. Prior to McKinsey, Tao worked as an Investment Fellow at Hatteras Venture Partners. Tao holds a Ph.D. in Biomedical Engineering from Johns Hopkins University and dual B.S. in Biology and Economics from Peking University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.